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ORIGINAL RESEARCH
Interleukin-17A Promotes Parietal Cell Atrophy
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SUMMARY
This study reports that interleukin-17A (IL-17A) is an
important contributor to parietal cell atrophy and meta-
plasia during chronic atrophic gastritis. IL-17A induces pa-
rietal cell apoptosis, while IL-17A neutralization in the
setting of gastritis limits atrophy and metaplasia.
BACKGROUND & AIMS: Atrophic gastritis caused by chronic
inﬂammation in the gastric mucosa leads to the loss of gastric
glandular cells, including acid-secreting parietal cells. Parietal cell
atrophy in a setting of chronic inﬂammation induces spasmolytic
polypeptide expressing metaplasia, a critical step in gastric
carcinogenesis. However, themechanisms bywhich inﬂammation
causes parietal cell atrophy and spasmolytic polypeptide
expressing metaplasia are not well deﬁned. We investigated the
role of interleukin-17A (IL-17A) in causing parietal cell atrophy.
METHODS: A mouse model of autoimmune atrophic gastritis
was used to examine IL-17A production during early and late
stages of disease. Organoids derived from corpus glands were
used to determine the direct effects of IL-17A on gastric
epithelial cells. Immunoﬂuorescent staining was used to
examine IL-17A receptors and the direct effect of signaling on
parietal cells. Mice were infected with an IL-17A-producing
adenovirus to determine the effects of IL-17A on parietal cells
in vivo. Finally, IL-17A neutralizing antibodies were adminis-
tered to mice with active atrophic gastritis to evaluate the
effects on parietal cell atrophy and metaplasia.
RESULTS: Increased IL-17A correlated with disease severity in
mice with chronic atrophic gastritis. IL-17A caused caspase-
dependent gastric organoid degeneration, which could not be
rescued with a necroptosis inhibitor. Parietal cells expressed IL-
17A receptors and IL-17A treatment induced apoptosis in
parietal cells. Overexpressing IL-17A in vivo induced caspase-3
activation and terminal deoxynucleotidyl transferase–mediated
deoxyuridine triphosphate nick-end labeling staining in
parietal cells. Finally, IL-17A neutralizing antibody decreased
parietal cell atrophy and metaplasia in mice with chronic
atrophic gastritis.
CONCLUSIONS: These data identify IL-17A as a cytokine
that promotes parietal cell apoptosis during atrophic gastritis,
a precursor lesion for gastric cancer. (Cell Mol
Gastroenterol Hepatol 2018;5:678–690; https://doi.org/
10.1016/j.jcmgh.2017.12.012)
Keywords: IL-17A; Atrophy; Metaplasia; Apoptosis.
See editorial on page 636.
Gastric cancer is a leading cause of cancer-relatedmortality in the world.1 Conditions that induce
chronic gastritis, such as Helicobacter pylori infection or
autoimmune gastritis, increase the risk for gastric
cancer.2,3 Most gastric cancers are adenocarcinomas that
develop over time because gastric epithelial cells are exposed
to chronic inﬂammation comprising various cytokines and
DNA-damaging compounds released by immune cells in the
gastric mucosa.4 A number of cytokine genes are associated
with an increased risk of gastric cancer;5–7 however, relatively
little is known about the pathophysiology of how cytokines
regulate the initiation and progression of the disease.
The Correa pathway proposes that gastric cancer
develops via a stepwise progression through a sequence of
histopathologic changes8,9: gastritis, oxyntic atrophy (loss of
parietal cells), metaplasia, dysplasia, and eventually
neoplasia.8 More recent studies have led to a molecular un-
derstanding of how the gastric epithelium responds to oxy-
ntic atrophy. The loss of parietal cells leads to increased
proliferation by gastric stem and progenitor cells10 and is
associated with metaplasia that is likely to arise from zymo-
genic chief cells recruited back into the cell cycle.11,12 These
metaplastic changes occur along with or in response to pa-
rietal cell death and inﬂammation, and are referred to as
spasmolytic polypeptide-expressing metaplasia (SPEM)
because of the expression of spasmolytic polypeptide (also
known as trefoil factor 2) by the metaplastic cells. SPEM,
which may represent a repair response to acute injury, also is
believed to be a precursor to gastric cancer when present for
long periods in chronically inﬂamed gastric mucosa.13,14
We previously have shown that suppressing inﬂammation
was effective at reducing parietal cell atrophy using the TxA23
mouse model of autoimmune gastritis.15–18 However, it is
unclearwhich cytokines are responsible for SPEMand parietal
cell atrophy both in this and other models. In this study we
focused on IL-17A, a proinﬂammatory cytokine secreted by
CD4þ T helper 17 cells (Th17) and other immune cells such
as CD8þ T cells, natural killer cells, and g-d T cells.19–21 The
receptor for IL-17A is composed of two protein monomers:
IL-17ReceptorA (IL17RA) and IL-17ReceptorC (IL17RC). The
IL-17 receptor complex is expressed on many cell types,
including various types of epithelial cells.22 Signals received
through IL-17R are known to induce genes involved in anti-
microbial responses, such as chemokines and antimicrobial
peptides.23,24 Importantly, IL-17A is secreted in response to
H pylori infection and in patients with autoimmune gastritis,
but howchronic exposure to IL-17Amayaffect gastric epithelial
cell biology is unknown.25,26 Recent studies have reported that
IL-17A-producing cells are present in the gastric mucosa in
human beings with gastric cancer, and that high frequencies of
IL-17A-producing cells correlated with more severe disease
and a poor prognosis, implicating a previously unrecognized
role for this cytokine in promoting gastric cancer.27–29
To determine the role IL-17A plays in promoting meta-
plasia and parietal cell atrophy we used the TxA23 mouse
model in which gastritis is induced by CD4þ T cells that are
autoreactive against the Hþ/Kþ adenosine triphosphatase
expressed by parietal cells. The TxA23 model mimics many
aspects of atrophic gastritis and metaplasia in human beings.
Similarities include chronic inﬂammation and parietal cell at-
rophy, mucous neck cell hyperplasia, SPEM, and, eventually,
gastric intraepithelial neoplasms.30,31 We identiﬁed immune
cells in the gastric mucosa that secrete IL-17A and observed
that, similar to human beings, high frequencies of IL-17A-
producing cells correlated with the degree of parietal cell at-
rophy and SPEM. Three-dimensional organoid cultures
derived from gastric corpus glands showed that IL-17A acts
directly on epithelial cells to induce organoid cell death, and
that IL-17A-induced organoid death could be inhibited with a
caspase-inhibiting compound (Z-VAD-FMK). We showed that
parietal cells express IL-17A receptors and undergo apoptosis
when treated with IL-17A. Infecting mice with an adenoviral
vector that increased systemic levels of IL-17A induced
caspase-3 activation and parietal cell apoptosis in vivo. Finally,
we tested the hypothesis that IL-17A plays a role in oxyntic
atrophy and SPEM development by administering an IL-17A-
neutralizing antibody to TxA23 mice with active
autoimmune gastritis. Anti-IL-17A treatment signiﬁcantly
reduced the extent of parietal cell atrophy and SPEM in mice
with autoimmune gastritis. Together, these ﬁndings showed
that IL-17A acts directly on parietal cells to trigger caspase-
mediated apoptosis and that neutralizing IL-17A can limit
the extent of parietal cell atrophy and the development of
metaplasia, two critical steps in gastric carcinogenesis.
Methods
Mice
TxA23mice express a transgenic T-cell–receptor speciﬁc for
a peptide from Hþ/Kþ adenosine triphosphatase a chain on a
BALB/c background, and have been described pre-
viously.16,30–32 BALB/c mice were purchased from Jackson
Laboratories. All mice were maintained in our animal facility
and cared for in accordance with institutional guidelines.
Studies were performed on a mixed group of male and female
mice with co-housed littermate controls. For neutralization
studies, mice were treated with 150 mg anti-mouse IL-17A
(BE0173, Clone 17F3; BioXCell, Lebanon, NH) or corresponding
isotype control (BE0083; BioXCell) biweekly for 4 weeks after
weaning via intraperitoneal injection. For IL-17A adenovirus
infection experiments, a recombinant adenovirus expressing
murine IL-17A, originally developed by Dr Jay Kolls (University
of Pittsburgh, Pittsburgh, PA)33 and generously provided by Dr
ShabaanaKhader (WashingtonUniversity, SaintLouis,MO),was
Abbreviations used in this paper: ADV, adenovirus; IL-17A, interleukin
17A; rIL-17A, recombinant interleukin 17A; SPEM, spasmolytic
polypeptide-expressing metaplasia; Th, T helper; TUNEL, terminal
deoxynucleotidyl transferase–mediated deoxyuridine triphosphate
nick-end labeling.
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propagated and puriﬁed as previously described.34 A control
recombinant adenovirus expressing b-galactosidase also was
used. BALB/c mice were given 5  109 50% Tissue Culture
Infective Dose of recombinant adenovirus encoding either re-
combinant murine IL-17A (IL-17A-ADV) or b-gal (control) by
tail vein injection.Micewere killed7–14days after infection and
serum IL-17A was measured by Th1/Th2/Th17 cytometric
bead array according to the manufacturer’s recommendations
(560283; BD Biosciences, San Jose, CA).
Histopathology
Stomachs were removed from mice, rinsed in saline,
immersion ﬁxed in 10% neutral-buffered formalin, parafﬁn
embedded, sectioned, and stained with H&E. For scoring,
investigators were blinded, and sections from individual
mice were assigned scores between 0 (absent) and 4
(severe) to indicate the severity of inﬂammation, oxyntic
atrophy, and neck cell hyperplasia.
Immunoﬂuorescence/Immunohistochemistry
Stomachs were prepared, stained, and imaged using
methods modiﬁed from Ramsey et al.35 The primary
antibodies used for immunostaining were as follows: rabbit
anti-IL-17RA (1:100, bs-2606R; BIOSS, Woburn, MA), goat
anti–vascular endothelial growth factor B (VEGF-B) (1:100,
sc-13083; Santa Cruz Biotechnology, Dallas, TX), and
anti-CD44v9 (1:10,000, LKGM002; Cosmo Bio, Carlsbad, CA).
Secondary antibody labeling was as described. For activated
caspase-3 immunohistochemistry, a Cell Signaling Technolo-
gies (Danvers, MA) SignalStain Apoptosis Kit (12692S) was
used according to the manufacturer’s protocol. For terminal
deoxynucleotidyl transferase–mediated deoxyuridine
triphosphate nick-end labeling (TUNEL) staining, an In Situ
Death Detection Kit (11684795910;Millipore-Sigma, St. Louis,
MO) was used according to the manufacturer’s speciﬁcations.
Slidesof glands for immunoﬂuorescencewere generatedusing
a Cytospin 4 centrifuge (A78300003; ThermoFisher,Waltham,
MA). Cells were ﬁxed on the slide in 4%paraformaldehyde for
20 minutes at room temperature and permeabilized (0.5%
bovine serum albumin, 0.1% Triton (VWR International,
Radnor, PA), and 2 mmol/L EDTA in phosphate-buffered sa-
line) for 30 minutes at room temperature before blocking and
staining according to the earlier-described protocols.
Image Cytometry Analysis
Immunoﬂuorescent images were segmented and indi-
vidual cells were enumerated using CellProﬁler (The Broad
Institute, Cambridge, MA) software. Resulting data ﬁles
were analyzed using FCS Express Image 6 (De Novo Soft-
ware, Glendale, CA).
Isolation of Immune Cells
The method for isolating cells from the stomach tissue has
been described previously.17,36 Brieﬂy, the gastric lymph
nodes were removed from the stomachs, homogenized, and
passed through a 40-mmol/L pore nylon ﬁlter. To detect
secreted cytokines, 1 106 cells were cultured in vitro in 15-
mL conical tubes containing 1 mL of supplemented RPMI.
Supernatants from cell cultures were collected after 48 hours,
and cytokines were measured using a Th1/Th2/Th17 cyto-
metric bead array according to the manufacturer’s recom-
mendations (560485; BD Biosciences).
Flow Cytometry
Cell surface staining was performed according to standard
procedures using antibodies against CD4 (562891; BD Phar-
mingen, San Diego, CA). Intracellular cytokine staining was
performed using antibodies against IL-17A (559502; BD Phar-
mingen). All ﬂow cytometry was performed on a BD LSRII (BD
Biosciences) or BD FACSCanto (BD Biosciences) and analyzed
using FlowJo (FlowJo, Ashland, OR). For intracellular cytokine
staining, cells were stimulated with phorbol myristate acetate
and ionomycin for 4 hours at 37C. Golgi-stop (BD Biosciences)
was added after 1 hour. Cells then were washed, ﬁxed in 4%
formyl saline, washed, and permeabilized (0.5% bovine serum
albumin, 0.1% Triton, and 2 mmol/L EDTA in phosphate-
buffered saline) for 30 minutes at room temperature. After
washing, cells were incubated overnight with the anticytokine
antibodies, and then washed and analyzed by ﬂow cytometry.
Gastroid/Gland Culture
Whole gastric glands isolated from the corpus of healthy
BALB/c mice were cultured in Matrigel (356234; Corning,
Tewksbury, MA) using gland culture media: Dulbecco’s modi-
ﬁed Eagle medium-F12 supplemented with EGF (PHG0313;
ThermoFisher), insulin-selenium-transferrin (I3146; Sigma-
Aldrich, St. Louis, MO), and hydrocortisone (H0888; Sigma-
Aldrich). Gastroids formed over a 48-hour period. At this time,
recombinantmurine IL-17A (576002;Biolegend, SanDiego, CA)
at 3 ng/mL was added to the cultures and gastroids were fol-
lowedup for size andviability over a3-day cultureperiod. ForZ-
VAD-FMK inhibition assays, Z-VAD-FMK (FMK001; R&D Sys-
tems,Minneapolis,MN)was added to gastroids at 3mmol/L. For
necrostatin-1 inhibition assays, necrostatin-1 (ab141053;
Abcam, Cambridge, UK) was added to gastroids at 20 mmol/L.
Gastroids were followed up for viability over a 3-day culture
period using photomicroscopy and ImageJ software version
1.49 (National Institutes of Health, Bethesda, MD).
For cultures of gastric glands, glands were suspended in
gland culture media and cultured for 24 hours. For IL-17A
gland treatment assays, recombinant IL-17A (rIL-17A) was
added to the treated conditions at 10 ng/mL.
Statistical Analysis
Data are expressed as means of individual determinations
± SE. Statistical analysis was performed by either the
Mann–Whitney U test or an unpaired Student t test using
GraphPad Prism 5 (GraphPad Software, San Diego, CA).
Results
IL-17A Production Correlates With Disease
Severity in Mice With Autoimmune Gastritis
Our ﬁrst goal was to determine the extent of IL-17A pro-
duction in amousemodel of autoimmune gastritis (TxA23T cell
receptor transgenic mice) that develops parietal cell atrophy
andSPEM.At2monthsof age, thesemicehave inﬂammationbut
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Figure 1. IL-17A production correlates with the severity of atrophic gastritis in TxA23 mice. (A) Representative H&E
sections showing the degree of parietal cell atrophy in healthy BALB/c (2 months old), 2-month-old TxA23, and 12-month-old
TxA23 mice. Yellow brackets indicate location of high magniﬁcation inset image. (B) Immunoﬂuorescent staining with
anti–VEGF-B (green), anti-CD44v9 (red), and Hoechst (blue) to illustrate the extent of parietal cell atrophy and SPEM devel-
opment in healthy mice, mice early in disease, and mice with advanced disease. (C) Representative ﬂow cytometry plots
showing the percentage of IL-17Aþ cells in the gastric lymph nodes of young and aged TxA23 mice. (D) The means ± SEM
showing signiﬁcantly higher percentages of IL-17Aþ cells in older TxA23 mice compared with younger mice. (E) Results of
enzyme-linked immunosorbent assays showing signiﬁcantly higher amounts of IL-17A secreted by cells isolated from older
TxA23 mice compared with younger mice. Each dot represents 1 mouse, 6–18 mice per group.
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mild degrees of atrophy, mucous neck cell hyperplasia, and
metaplasia, compared with 8- to 12-month-old mice, which
have severe atrophy, hyperplasia, and metaplasia (Figure 1A).
Immunoﬂuorescent staining was used to assess the develop-
ment of SPEM using antibodies against CD44v9, a splice variant
form of CD44 that has been established as a reliable marker of
SPEM,37 showing that 2-month-old mice develop focal SPEM
lesions, whereas 12-month-old mice have widespread and se-
vere SPEM lesions (Figure 1B). Immune cellswere isolated from
the gastric lymph nodes of 2-month-old and 12-month-oldmice
and the percentage of IL-17A-producing immune cells were
determined by intracellular cytokine staining. IL-17A-
producing cells were present in both young and old mice,
however, the frequency of IL-17Aþ cells was>6 times higher in
the gastric lymph nodes of older mice compared with younger
mice (2.6 ± 0.8 vs 0.4 ± 0.1; P ¼ .02) (Figure 1C and D). The
amounts of IL-17A protein secreted by cells isolated from
younger and older mice also was determined, and cells from
oldermice secreted greater than 50-foldmore IL-17A than cells
isolated from younger mice (1582 ± 1018 vs 25 ± 5 pg/mL;
P¼ .01) (Figure 1E). These data show that IL-17Aproduction in
this mouse model correlates with the progression of gastritis
toward gastric neoplasia, a ﬁnding that also was reported in
recent studies of human beings with gastric cancer.27–29
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Figure 2. IL-17A induces the caspase-dependent death of corpus gastroids in vitro. Corpus glands were isolated and
cultured in Matrigel in gastroid-forming conditions. Red arrows denote degenerated organoids. (A) Gastroids were cultured for
48 hours and then media was supplemented with IL-17A. Gastroid death was compared between IL-17A supplemented and
controls. (B) Representative immunoﬂuorescent images of control and IL-17A-treated organoids stained with Hoechst (blue)
and TUNEL (green). (C) Gastroids were cultured for 48 hours and then media was supplemented with IL-17A or IL-17A þ a
pan-caspase inhibitor, ZVAD-FMK, or IL-17A þ a necroptosis inhibitor, necrostatin-1. Red arrows denote dead organoids in
each ﬁeld of view. (D) Percentage of degenerated organoids in control, IL-17A-treated, IL-17A þ ZVAD-FMK, and IL-17A þ
necrostatin-1 conditions. Data are the means ± SEM of 3 experiments with 8–12 cultures per group. Signiﬁcance was
calculated using the Student t test.
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IL-17A Acts Directly on Gastric Epithelium and
Induces Caspase-Dependent Apoptosis
The previous results indicated that increases in disease
severity during ongoing chronic inﬂammation could be owing
to effects of increased IL-17A in the local cytokine milieu. We
hypothesized that these effects were caused by IL-17A
signaling directly into gastric epithelium. To test this we
generated 3-dimensional spheroids from glands dissociated
from the gastric corpus mucosa, known as gastric organoids
or gastroids.38 These gastroids allowed us to examine the
direct effect(s) of IL-17A on gastric epithelial cells. Recom-
binant IL-17A (rIL-17A)was added to gastroids that had been
cultured without stem cell growth factors. Gastroids were
analyzed for degeneration using photomicroscopy. The
addition of rIL-17A to these epithelial cell cultures caused
organoid degeneration in a dose-dependent manner
(Supplementary Figure 1). By using the dose determined to
cause 50% degeneration, 3 ng/mL, we observed a signiﬁcant
increase in organoid degeneration on day 3 (Figure 2A). We
hypothesized that IL-17Amight be inducing programmed cell
death, leading to organoid degeneration, and used TUNEL to
assess this hypothesis. We observed that organoids induced
to degenerate by IL-17A contained a larger number of
TUNELþ cells (Figure 2B). Next, we wanted to determine
whether the IL-17A-induced cell death in the organoids was
caused by apoptosis (caspase-dependent) or
necroptosis (Receptor-interacting serine/threonine-protein
kinase 3-dependent). To distinguish between these
2 death pathways we cultured organoids with an irreversible
pan-caspase inhibitor (Z-VAD-FMK) or necrostatin-1 (Nec-1),
a compound shown to inhibit enzymes necessary for the
necroptotic pathway.39 Z-VAD-FMK signiﬁcantly reduced the
amount of IL-17A-induced organoid degeneration but Nec-1
did not (Figure 2C and D). Together, these data show that
IL-17A acts directly on gastroids, and that a primary effect of
IL-17A in the gastroid cultures was to induce caspase-
dependent apoptosis.
Parietal Cells Express IL-17A Receptors and
Undergo Apoptosis When Treated With IL-17A
There is a lack of information about which cytokine
receptors are expressed by epithelial cells in the gastric mu-
cosa. Our observations using in vitro organoid cultures
conﬁrmed that IL-17Ahas effects on gastric epithelial cells, but
did not elucidate which cell type(s) were responsible for the
observed degeneration. We wanted to determine if parietal
cells were capable of responding to IL-17A and if this response
was promoting atrophy directly. We used immunoﬂuores-
cence to examine IL-17RA expression in the gastric mucosa of
healthy BALB/c mice. Tissues were stained with antibodies
against IL-17RA and VEGF-B to detect parietal cells
(Figure 3A), and positive cells were determined using isotype
controls (Supplementary Figure 2). These studies identiﬁed
parietal cells as expressing the IL-17A receptor. Next, we used
image cytometry software to quantify the staining intensity of
VEGF-Bþ parietal cells relative to all other cells (Figure 3B).
Image cytometry software uses data compiled by a cell seg-
mentation software platform to analyze ﬂuorescence intensity
of immunoﬂuorescent images on a per-cell basis. Shown in
Figure 3B is the gating strategy for identifying parietal cells
(red) and all other cells (blue) in an immunoﬂuorescent image
based on VEGF-B intensity. This analysis identiﬁed parietal
cells as staining for IL-17RAat a higher intensity thannearly all
other cell types as shown in the representative histograms.We
next sought to determine if IL-17A induced parietal cell death.
To do this, we cultured freshly isolated gastric glands from
healthy BALB/c mice in the presence or absence of IL-17A for
24 hours. After 24 hours in culture, slides were generated
using a Cytospin centrifuge and immunoﬂuorescently stained
for VEGF-B and TUNEL (Figure 3C). Although there is some
parietal cell apoptosis associated with the experimental con-
trols, we observed a signiﬁcant increase in the percentage of
TUNELþ parietal cells above this background in the IL-17A-
treated cultures (60.8 ± 5.6 vs 22.0 ± 3.2; P < .001)
(Figure 3D). TUNELþ non–parietal cells were relatively rare in
both control and IL-17A-treated conditions (data not shown).
IL-17A Production Is Sufﬁcient to Cause Parietal
Cell Apoptosis In Vivo
Having shown that IL-17A acted directly on the gastroid
cultures and induced caspase-dependent death, and that IL-
17A induced parietal cell death in gastric gland cultures, we
sought to determine whether IL-17A could induce apoptosis
of gastric epithelial cells in vivo. To do this, we infected co-
horts of BALB/c mice with a recombinant IL-17A-producing
adenovirus (IL-17A-ADV) or with b-galactosidase–express-
ing adenovirus as a control (b-gal–ADV). Infectionwith the IL-
17A-ADV increased serum levels of IL-17A to 20–70 ng/mL
compared with less than 1 ng/mL in the serum of
b-gal–ADV–infected mice. Levels of interferon-g, IL2, IL4,
tumor necrosis factor a, IL6, or IL10 were not signiﬁcantly
different between IL-17A-ADV compared with controls (data
not shown). After conﬁrming increased serum IL-17A in IL-
17A-ADV–infected mice, we evaluated gastric tissue sections
Figure 3. (See previous page). Parietal cells express IL-17A receptor. (A) Representative immunoﬂuorescent staining of
healthy BALB/c (2 months old) mouse gastric corpus for Hoechst (blue), VEGF-B (red), and IL-17RA (yellow). A magniﬁcation
pane is outlined in white showing the expression of IL-17RA on VEGF-B–expressing parietal cells. (B) Image cytometry
software was used to quantify the intensity of IL-17RA ﬂuorescence on parietal cells using immunoﬂuorescent images. Shown
is a representative plot of VEGF-B–positive parietal cells (red) and VEGF-B–negative cells (blue) with histograms of IL-17RA
staining intensity in each of these groups. Epithelial cells isolated from the gastric corpus of BALB/c mice (2 months old) were
cultured in media or media supplemented with IL-17A for 24 hours. Cytospin slides were generated from control and treated
glands for microscopic analysis. (C) Representative immunoﬂuorescent staining of Cytospins generated from cultured gastric
epithelial cells stained with Hoechst (blue), anti–VEGF-B (red), and TUNEL (green). (D) TUNELþ parietal cells were quantiﬁed as
a percentage of total parietal cells (PCs). Data are means ± SEM of 10 representative images prepared from 6 slides over 2
separate experiments.
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using an antibody that recognizes the activated form of
caspase-3 to determine the number of epithelial cells under-
going apoptosis in both groups of mice 1–2 weeks after the
infections. We observed many more activated caspase-
3–positive parietal cells in IL-17A-ADV–treated mice
compared with controls (Figure 4A). We also observed that
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the majority of activated caspase-3–positive cells in the IL-
17A-ADV–treated stomachs were parietal cells based on
morphology. A quantiﬁcation of the number of activated
caspase-3–positive parietal cells from 3 complete cross-
sections of gastric corpus in each mouse showed a signiﬁ-
cant (4-fold) increase in the IL-17A-ADVmice compared with
controls (mean± SE, 40.5± 6.9 for IL-17A-ADV, and 8.5± 4.8
for controls; P ¼ .001) (Figure 4B). To ensure accurate iden-
tiﬁcation of apoptotic parietal cells, we used immunoﬂuo-
rescent staining to identify VEGF-Bþ cells that also stained
TUNELþ (Figure 4C). We quantiﬁed VEGF-Bþ TUNELþ
double-positive cells in 3 representative 20 ﬁelds of view
from each treated mouse and observed a signiﬁcant increase
in the absolute number of TUNELþparietal cells in the IL-17A-
ADV cohort comparedwith the controls (6.0±1.0 vs 1.2±0.3;
P¼ .006) (Figure 4D). These results show that IL-17A induces
caspase-3 activation and parietal cell atrophy in vivo.
Administering Anti-IL-17A Reduces Parietal Cell
Atrophy and SPEM During Chronic Gastritis
Previous results showed that in vitro gastric epithelial
cell cultures degenerate in a caspase-dependent manner in
the presence of IL-17A; that parietal cells express IL-17RA,
speciﬁcally under apoptosis when cultured with IL-17A; and
that parietal cells respond to in vivo overexpression of IL-
17A with increased frequency of caspase-3–mediated
apoptosis. Because of these data, we hypothesized that if IL-
17A was inducing parietal cell apoptosis, then neutralizing
IL-17A in mice with ongoing autoimmune gastritis might be
an effective means to reduce the degree of parietal atrophy
and subsequent metaplasia. To test this hypothesis, a cohort
of TxA23 mice received injections of a monoclonal antibody
to neutralize IL-17A over a 4-week period of time beginning
at weaning and concluding at 2 months of age. The
severity of atrophy and SPEM was compared between
anti-IL-17A–treated TxA23 and control TxA23 mice after 4
weeks of treatment. An analysis of stomach sections stained
with H&E showed that mice treated with the IL-17A-
neutralizing antibody had signiﬁcantly less severe parietal
cell atrophy in the anti-IL-17A mice compared with control
mice (1.1 ± 0.1 vs 1.7 ± 0.2; P ¼ .015) (Figure 5A and B). In
addition, staining gastric tissue sections with a parietal
cell–speciﬁc antibody (anti–VEGF-B) conﬁrmed that
mice treated with anti–IL-17A had signiﬁcantly less
CD44v9þ gastric units compared with untreated mice
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(8 ± 4 vs 30 ± 5; P ¼ .008) (Figure 5D). Together, these data
show that neutralizing IL-17A is an effective means to
reduce the extent of parietal cell atrophy and SPEM in mice
with active and ongoing gastritis.
Discussion
Chronic inﬂammation that causes parietal cell atrophy
and metaplasia increases the risk for gastric cancer.8,9
Although the importance of parietal cell loss in the devel-
opment of SPEM is well established, the signals that cause
parietal cell death and induce metaplastic changes in sur-
rounding epithelium are currently not well understood. The
mechanisms causing parietal cell death are critical because
the key cellular event in increased gastric cancer risk seems
to be whether chronic inﬂammation causes parietal cell
death; in other words, whether superﬁcial gastritis pro-
gresses to chronic atrophic gastritis. By using the TxA23
mouse model of autoimmune gastritis and inﬂammation-
induced metaplasia, we showed that IL-17A-producing
immune cell abundance in the gastric mucosa and the con-
centration of IL-17A produced by these cells correlated with
the degree of atrophy and metaplasia. The recent reports
that IL-17A levels correlate with gastric cancer progression
and poor prognosis in human beings motivated us to
examine a direct atrophy/metaplasia-inducing role of IL-
17A on the gastric epithelial cells themselves. The data
presented in this study show that IL-17A induces caspase-
dependent death of gastric organoids, induces caspase-3
activation and parietal cell apoptosis in vitro and in vivo,
and can be neutralized to reduce the extent of parietal cell
atrophy and SPEM in mice with ongoing atrophic gastritis.
We previously used the TxA23 model of chronic atrophic
gastritis to show that CD4þ Th17 cells, which produce many
cytokines in addition to IL-17A, were present and contrib-
uted to disease. Furthermore, Th17 cells induced a more
severe atrophic gastritis phenotype compared with CD4þ T
cells differentiated into Th1 or Th2 cells.25 The current
study shows that IL-17A is involved directly in the loss
of parietal cells from the gastric mucosa, providing
mechanistic insight into the pathogenicity of Th17 cells
during chronic atrophic gastritis.
IL-17A is a pleotropic cytokine that is widely known for
its ability to induce proinﬂammatory genes by various types
of epithelial cells. In our study, direct administration of IL-
17A to epithelial organoids caused TUNELþ degeneration,
and this degeneration subsequently was inhibited by Z-VAD.
This degeneration was not prevented by necrostatin-1, a
known inhibitor of the necroptotic pathway,39 indicating
apoptosis as the mechanism of organoid degeneration. In
addition, in vivo studies using the IL-17A-producing
adenoviral vector induced caspase-3 activation and
TUNELþ staining that was detected almost exclusively in
parietal cells. Finally, we observed that IL-17A was critical
to the progression of chronic atrophic gastritis in which
many different cytokines are active. We determined that
neutralizing IL-17A in mice with autoimmune gastritis
reduced the degree of parietal cell atrophy and SPEM. From
these data, we conclude that parietal cells respond to IL-17A
by undergoing apoptosis, which promotes the development
of atrophy and metaplasia during chronic inﬂammatory
processes in which IL-17A is produced in excess. Although it
is conceivable that the effect of IL-17A on parietal cells is the
indirect result of actions on other gastric epithelial cell types
that express the receptor, it is most likely the result of direct
interaction with parietal cells. Reports of IL-17A inducing
apoptosis are not common, but IL-17A has been reported to
activate caspase-3/9 and induce apoptosis of vascular
endothelial cells and cardiomyocytes.40,41
Although the homeostatic function of IL-17A–induced
apoptosis of parietal cells is not clear, it is possible that
parietal cells, which secrete large amounts of acid as a part
of their physiologic role, respond to some inﬂammatory
signals such as IL-17A by undergoing apoptosis to protect
the tissue from additional damage during a disease process.
Under acute circumstances the parietal cells are likely to be
replaced as inﬂammation is resolved and the gastric mucosa
regenerates. The metaplastic proliferation seen in acute at-
rophy is likely the attempt to generate new parietal cells,
but in a setting of chronic inﬂammation it is plausible that
parietal cells are constantly signaled to undergo apoptosis
and the metaplasia never resolves. This hypothesis is
strengthened by the observation that inﬂammatory signals
in addition to parietal cell death are required for metaplastic
transformation.10
IL-17A has been reported to have protective effects in
mouse models of H pylori infection.42,43 Because IL-17A-
deﬁcient mice develop less severe gastritis in response to
infection,44 protective effects may depend on whether the
infection is viewed from the acute or chronic standpoint. IL-
17A may play a protective role in limiting acute infection
while also contributing to gastric pathology under chronic
inﬂammatory conditions, such as H pylori infection and
autoimmune gastritis. Knowing that IL-17A acts directly on
gastric epithelial cells and promotes parietal cell atrophy is
an important piece of a complicated puzzle: the mechanism
by which the complex milieu of cytokines in any individual
patient inﬂuences whether gastritis progresses to atrophic
gastritis, metaplasia, dysplasia, and neoplastic trans-
formation. This provides key mechanistic insight into the
mounting evidence in both human beings and in mouse
models that IL-17A levels are associated with the severity of
gastritis and gastric cancer development.27–29
This study identiﬁes IL-17A as a critical component of
the inﬂammatory microenvironment that induces parietal
cell death, but certainly not the only pathogenic cytokine
driving disease progression. We hypothesize a scenario in
which a complex milieu of cytokines participates in a
cross-talk between immune and gastric epithelial cells,
some of which serve to drive disease progression and
others that inhibit preneoplastic epithelial cell changes.
The types and amounts of cytokines made by any indi-
vidual could play a role in determining the severity of
inﬂammation, degree of parietal cell atrophy, the type of
metaplasia, and ultimately whether disease progresses to
neoplasia. This view is supported by our ﬁnding that
neutralizing IL-17A signiﬁcantly inhibits but does not
completely reverse parietal cell atrophy in the context of
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ongoing gastritis, as well as data from multiple labora-
tories showing the importance of a number of soluble
signaling molecules such as sonic hedgehog,45,46 IL-33,47
and IL-1148 in atrophic gastritis and gastric preneoplasia.
Additional studies are required to provide a better un-
derstanding of the interface between the immune system
and the gastric epithelium in both homeostatic and disease
settings. The complex interactions between cytokine sig-
nals that promote and inhibit the progression of gastritis
to preneoplasia are just beginning to be elucidated. Human
studies also are needed to properly assess the role of IL-
17A on parietal cells in both the steady state and in
response to acute and chronic inﬂammation. An under-
standing of what cytokines inhibit the actions of IL-17A
also are important to understanding the key regulatory
mechanisms governing the atrophy of parietal cells and the
development of SPEM during chronic inﬂammation. This
information may help develop strategies to diagnose in-
dividuals with a high risk of progressing from atrophic
gastritis to gastric cancer and perhaps even to develop
new treatments that target cytokines such as IL-17A.
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Figure 1. Dose-dependent
gastroid killing by rIL-17A.
Primary gastroids were
cultured for 3 days in various
concentrations of IL-17A
andassessed for viability. (A)
Representative images of
gastroids on day 3 at
differing concentrations of
IL-17A. (B) Percentage
of gastroid death per
culture per day. Data are
means ± SEM of 2 experi-
ments with 4 cultures per
group.
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Figure 2. IL-17RA stain-
ing compared with iso-
type control. (A) Staining
of healthy BALB/c gastric
corpus tissue with irrele-
vant rabbit IgG (left) and
(B) rabbit anti-IL-17RA
(right). Images were ac-
quired using identical mi-
croscope settings and
subjected to identical
brightness/contrast
settings.
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